Targeting the polymerase and endonuclease activities of the L protein of human pathogenic mammarenaviruses

Active Grant Awarded

Award ID
R01AI194636
Recipient
Awarding agency
Obligated
$1,620,145

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 7% complete
Place of performance
La Jolla, CA 92037, USA

Award details come from USAspending.gov.

About this award

The National Institutes of Health's National Institute of Allergy and Infectious Diseases, within the Department of Health and Human Services, awarded Grant R01AI194636 to The Scripps Research Institute, with $1.620145 million obligated, on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds work on the polymerase and endonuclease activities of the L protein of human pathogenic mammarenaviruses, chiefly Lassa virus and Junin virus, which cause hemorrhagic fever, along with lymphocytic choriomeningitis virus. No FDA-licensed vaccines exist for these viruses.

The project advances two lead inhibitors, MCOT466 (polymerase) and MCPB916 (endonuclease). The recipient will define their mechanisms of action and viral escape, assess broad-spectrum antiviral activity against a panel of hemorrhagic fever-causing mammarenaviruses and other bunyavirales of concern, and evaluate in vivo efficacy while minimizing off-target liabilities. Medicinal chemistry and ADMET studies will identify analogs or prodrugs with optimal pharmacokinetic, pharmacodynamic, and toxicokinetic features for development as oral antivirals.

Work is performed in La Jolla, California 92037, with ultimate completion on June 30, 2031. A cost-reimbursable subaward dated September 9, 2026 flows to Texas Biomedical Research Institute, doing business as Southwest Foundation for Biomedical Research.

Description

Abstract
Several mammarenaviruses (MAAV), chiefly lassa (LASV) in western africa and junin (JUNV) in the argentinean pampas, cause hemorrhagic fever (HF) disease in humans and pose important public health problems in their endemic regions. In addition, the globally distributed MAAV lymphocytic choriomeningitis virus (LCMV) is an underrecognized human pathogen of clinical significance in neonatal infections, and a serious threat to immunocompromised people. Moreover, LASV and JUNV pose credible biodefense threats and are category a agents. No FDA-licensed vaccines exist for MAAV, and current therapy is limited to the off-label use of ribavirin whose efficacy remains controversial. Hence, the significance to human health of developing novel therapeutics to combat human pathogenic MAAV. We have identified potent novel lead compound inhibitors of the polymerase (MCOT466) and endon (MCPB916) activities of the old world (LCMV and LASV), and the distantly related new world JUNV) MAAV L proteins. The central goal of this proposal is to define the mechanisms of action, broad-spectrum anti-MAAV potential, and in vivo efficacy of these inhibitors while minimizing off-target liabilities. To reach these goals, we will complete the following studies: 1) we will use a combination of biochemical, cell-based functional, structural, and viral genetics studies to gain a detailed understanding of MCOT466 and MCPB916 mechanisms of action, mechanisms of viral escape and biological properties of drug-resistant viruses. 2) we will assess the broad-spectrum antiviral activity of MCOT466 and MCPB916 against a panel of known HF- causing MAAV, and other non-MAAV bunyaviricetes of concern. 3) we will pursue medchem and admet studies to identify MCOT466 and MCPB916 analogs/prodrugs with optimal PK, PD and TK features for their development as oral antivirals. 4) we will assess the in vivo prophylactic and therapeutic efficacy of optimized MCOT466 and MCPB916 analogs/prodrugs in mono-and combination therapy modes in validated animal models of LASV, and JUNV lethal infections. The successful completion of the proposed studies will generate the data and knowledge required for subsequent IND-enabling studies and advanced nonclinical studies for oral preclinical polymerase and endon inhibitors, suitable for combination therapy, with potent and broad- spectrum MAAV activity to treat infections by human pathogenic MAAV, and other non-MAAV bunyaviricetes of concern associated with severe disease and death in humans.

Subawards

Subrecipient Amount Awarded
Texas Biomedical Research Institute Awards a cost reimbursable subaward $198,000

Quick answers

Who received award R01AI194636?

R01AI194636 was awarded to Scripps Research Institute by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 16, 2026.

How much is award R01AI194636 worth?

$1,620,145 has been obligated on R01AI194636.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award